Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 319

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Advances in the prevention of Alzheimer's disease and dementia

Open access
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., Fratiglioni, L., Hooshmand, B., Khachaturian, A. S., Schneider, L. S., Skoog, I., Kivipelto, M. · 2014 · Journal of Internal Medicine

Abstract

Background: Definitions and diagnostic criteria for all medical conditions are regularly subjected to reviews and revisions as knowledge advances. In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to undergo major re‐examination. The shift towards presymptomatic and pre‐dementia stages of AD has brought prevention and treatment trials much closer to each other than before. Methods: Here we discuss: (i) the impact of diagnostic reliability on the possibilities for developing preventive strategies for AD; (ii) the scientific evidence to support moving from observation to action; (iii) ongoing intervention studies; and (iv) the methodological issues and prospects for balancing strategies for high‐risk individuals with those for broad population‐based prevention. Results: The associations between neuropathology and cognition are still not entirely clear. In addition, the risk factors for AD dementia and the neuropathological hallmarks of AD may not necessarily be the same. Cognitive impairment has a clearer clinical significance and should therefore remain the main focus of prevention. Risk/protective factors for dementia/AD need to be studied from a life‐course perspective. New approaches in prevention trials include enrichment strategies based on genetic risk factors or beta‐amyloid biomarkers (at least four ongoing pharmacological trials), and multidomain interventions simultaneously targeting various vascular and lifestyle‐related risk factors (at least three ongoing trials). Experience from prevention programmes in other chronic diseases can provide additional methodological improvements. Conclusions: Building infrastructures for international collaborations is necessary for managing the worldwide public health problem of AD and dementia. The International Database on Aging and Dementia (IDAD) and the European Dementia Prevention Initiative (EDPI) are examples of ongoing international efforts aiming to improve the methodology of preventive studies and provide the basis for larger intervention trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/joim.12178

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. Williams JW, 2010, Preventing Alzheimer's Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193. (Prepared by the Duke Evidence‐Based Practice Center Under Contract No. HHSA 290‐2007‐10066‐I.)
  2. Rothman KJ, 2008, Causation and Causal Inference Modern Epidemiology, 5
  3. RosesAD Welsh‐BohmerKA BurnsDKet al.A Pharmacogenetics‐Supported Clinical Trial to Delay Onset of Mild Cognitive Impairment due to Alzheimer's Disease 5th Conference Clinical Trials on Alzheimer's Disease.Monte Carlo:The Journal of Nutrition Health & Aging 2012;841.
  4. 10.1007/s12603-013-0004-0 · doi:10.1007/s12603-013-0004-0

Cited by

See all 319

Metadata

Authors
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., Fratiglioni, L., Hooshmand, B., Khachaturian, A. S., Schneider, L. S., Skoog, I., & Kivipelto, M.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2014-03
Volume
275
Issue
3
Pages
229-250
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2043715766
Cited by
319
References
102
FWCI
25.38
Type
journal article
Language
en
Open access
green
Funders
  • NIH (P50 AG05142, R01 AG033288, R01 AG037561)
  • Baxter
  • Genentech
  • Johnson & Johnson
  • Eli Lilly
  • Lundbeck
  • Novartis
  • Pfizer
  • TauRx

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.